NEW YORK (GenomeWeb) – Human Longevity today announced an agreement to license, develop, and co-promote Celgene Cellular Therapeutics' placental cell population, PSC-100.
As part of the deal, CCT, a Celgene company, has made an equity investment of an undisclosed amount into La Jolla, Calif.-based Human Longevity. Other terms of the deal were not disclosed.
Human Longevity will use its expertise and technology to sequence and characterize PSC-100 at the molecular level, complementing CCT's PSC-100 data gathered from Phase I human studies. Human Longevity said it has the option to explore a variety of applications for the cell population, including sarcopenia, which is associated with aging characterized by a degenerative loss of skeletal muscle mass, quality, and strength.
"We think that cellular-based therapeutics combined with our genomics-based discovery systems offer exciting potential for age-related diseases," Human Longevity CEO and Co-founder J. Craig Venter said in a statement. "PSC-100 provides an advanced basis of testing cell therapy for diseases like sarcopenia."
Human Longevity was founded in March to combine human genome, microbiome, and metabolome data with clinical information to progress the development of new diagnostics, therapeutics, and stem cell treatments for aging-related diseases.
Another co-founder of Human Longevity is Robert Hariri, who is the chairman, founder, CSO, and former CEO of CCT.